

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/052,961	BERGER, JOSEPH R.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Russell Travers, J.D., Ph.D	1617	

**All Participants:**

(1) Russell Travers, J.D., Ph.D.

(2) Gary Gershik.

**Status of Application: \_\_\_\_\_**

(3) \_\_\_\_\_.

(4) \_\_\_\_\_.

**Date of Interview:** 21 April 2004

**Time:** \_\_\_\_\_

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description: \_\_\_\_\_

**Part I.**

Rejection(s) discussed:

Claims discussed:

*all claims*

Prior art documents discussed:


*All prior art*

**Part II.**
**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

*Applicant believes 7.5mg dosage is not obvious over 5mg dosage, Examiner does not agree. Examiner notes Eisenber was provided after final, and does not render the claims unobvious.*

**Part III.**

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  
 RUSSELL TRAVERS  
 PRIMARY EXAMINER  
 GROUP 1200

\_\_\_\_\_  
(Examiner/SPE Signature)

\_\_\_\_\_  
(Applicant/Applicant's Representative Signature – if appropriate)